Company intelligence / Profile preview

Chuang Yi Global Asset Management

Taiwan

Ownership: Private
Development stage: Other

Overview

Chuang Yi Global Asset Management holds exclusive Taiwanese rights to develop and commercialize DB104 (liafensine) for treatment-resistant depression. The drug demonstrated robust efficacy and safety in a recent Phase 2b biomarker-selected trial, enabled by a pharmacogenomic biomarker within the ANK3 gene discovered by Denovo Biopharma

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Investors

Partnerships

Denovo Biopharma

Beyond the preview

Go deeper on Chuang Yi Global Asset Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chuang Yi Global Asset Management.

Explore the full profile